Using a face mask, Adelaide researchers have a new way to detect a major hidden equine health issue.
Up to 80 percent of horses – including racehorses and showjumpers – suffer from a form of asthma that affects their performance and wellbeing.
Researchers led by veterinarian Surita Du Preez from the University of Adelaide are designing a way to detect the condition – which often produces no obvious symptoms – without adding further stress to the affected animals.
“Currently the methods that are available to diagnose the mild to moderate form of horse asthma are invasive,” says Surita.
Professor Mark Kendall is planning to dispatch the 160-year-old needle and syringe to history. He’s invented a new vaccine technology that’s painless, uses a fraction of the dose, puts the vaccine just under the skin, and doesn’t require a fridge.
The Nanopatch is a 1 cm square piece of silicon with 20,000 microscopic needles engineered on one side. Coat the needles with dry vaccine, push it gently but firmly against the skin, and the vaccine is delivered just under the outer layer of skin.
It’s a technology he invented in response to a call from the Bill and Melinda Gates Foundation seeking ideas for delivery of vaccines in developing countries—where it’s a challenge to keep conventional wet vaccines cold to the point of delivery.
Across Japan teeth are being made stronger with chewing gum and other products using an ingredient discovered in Australian dairy milk.
Now an innovative Japanese company is taking the Australian discovery to dental surgeries around the world.
“Our discovery was based on milk, to develop a delivery system of calcium phosphate to make teeth stronger,” says Eric Reynolds, from The University of Melbourne.
Clinical trials of the chewing gum showed that it helps stop tooth decay and helps reverse early stages of tooth decay.
“The Recaldent chewing gum was very successful in Japan and the leading dental supply company in Japan, GC Corporation, then became interested in the technology.”
“We’ve developed materials for repair of tooth decay and damage but now we’re focusing on prevention and protection collaborating with Melbourne University,” says Satoshi Tosaki from GC Corporation.
“One of those products is a cream, in Australia it’s called Tooth Mousse, that’s sold to dentists to strengthen patients’ teeth and that’s now sold in more than 50 countries worldwide,” he says.
“I’ve really enjoyed working with GC because I’ve learnt a lot from them in terms of business. But I think the most gratifying thing is that their products actually help people, and substantially reduce the burden of oral disease,” Eric says.
Malaria kills 500,000 people every year. And 90 per cent of those are children. Griffith University researchers are screening hundreds of thousands of compounds supplied by Japanese companies to find the right compound with activity against the malaria parasite.
Japan’s Global Health Innovative Technology Fund is supporting the research as part of their search for new ways to fight malaria.
“GHIT is a fund that invests in partnerships between Japanese and non-Japanese entities,” says BT Slingsby, the Executive Director of GHIT.
“Many of those entities are in Australia including The University of Melbourne, The Walter and Eliza Hall Institute, and Griffith University.”
“Currently we’re working with companies such as Daiichi-Sankyo, Takeda, Mitsubishi Tanabe, and Eisai,” says Griffith University’s Vicky Avery.
They bring those compounds to us. We then dispense them into plates which contain the parasite we’re trying to kill. After they’ve been incubated for a period of time we then look to see whether they’ve had an effect in killing the parasites.
“Once one defines a hit, usually it’s the pharmaceutical company that drives forward the further development of that compound to create a drug.
“This collaboration is fantastic in that it has three groups who complement each other,” Vicky says.
The Japanese pharma companies bring expertise in drug discovery and development. GHIT has managed to pull together significant funding from both global partners as well as the Japanese Government. And Griffith University brings the biology expertise.
The conditions have been right for Zika virus to spread during the warmer months of past years in Townsville, Cairns and Rockhampton, according to research led by the Australian Red Cross Blood Service.
Using temperature data from January 2015 to December 2016, the team modelled the ability of mosquitoes to spread the virus in four Queensland cities. Brisbane (the fourth city) was the only site where the risk was low.
“If locations experience outbreaks of dengue, the conditions would also be right for outbreaks of Zika,” says lead researcher Dr Elvina Viennet.
The findings emphasise the need for imported cases to be reported immediately, Elvina says.
Indonesian and Australian researchers are working together to combat two big killers: pneumonia, and tuberculosis.
Around six million young Indonesians catch pneumonia each year, according to a 2008 study, and it’s the number one killer of children under five. Researchers now think there might be a link to how much time kids are spending out in the sunshine—more specifically, their level of vitamin D.
A new mapping tool will help shape a healthier Australia through sport and recreation.
Developed by researchers at Victoria University and Federation University Australia, the Sport and Recreation Spatial tool is a consolidated national database combining data on exercise, recreation and sport participation as well as demographic and health statistics. It also includes information on existing sports venues and organisations.
A new diagnostic system used to detect cancer cells in small blood samples could next be turned towards filtering a patient’s entire system to remove those dangerous cells – like a dialysis machine for cancer – says an Australian researcher who helped develop the system.
The technique was developed for cancer diagnosis, and is capable of detecting (and removing) a tiny handful of cancer-spreading cells from amongst the billions of healthy cells in a small blood sample.
The revolutionary system, which works to diagnose cancer at a tenth of the cost of competing technologies, is now in clinical trials in the US, UK, Singapore and Australia, and is in the process of being commercialised by Clearbridge BioMedics PteLtd in Singapore.